Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE: 300497)
Health Care · Pharmaceuticals · CN
CN¥17.32
-5.87% today · +58.9% 1Y
Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE: 300497) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.39B and employs 1,663 people.
Over the last twelve months the share price has gained 58.9%, trading between 9.40 and 24.18.
Tweenvest scores Jiangxi Fushine Pharmaceutical Co., Ltd. across four factors: quality 55/100, value 47/100, growth 3/100. Its strongest factor is quality.
300497 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.39B
- Revenue (TTM)
- $229.44M
- P/E
- 63.56
- EPS
- 0.27
- Dividend yield
- 0.58%
- Beta (5Y)
- 0.16
- 52-week high
- CN¥24.18
- 52-week low
- CN¥9.40
- Avg volume (3M)
- —
- Shares outstanding
- 538.65M
- Employees
- 1,663
- Next earnings
- —
About Jiangxi Fushine Pharmaceutical Co., Ltd.
Jiangxi Fushine Pharmaceutical Co., Ltd. is engaged in the global research, development, production, and marketing of active pharmaceutical ingredients (APIs) and key chemical compounds for drug synthesis. Its product portfolio includes important antibiotics like penicillin and carbapenem, alongside a variety of other pharmaceutical offerings. The company also extends its expertise by providing contract research, development, and manufacturing services. Founded in 2002 and headquartered in Jingdezhen, China, the firm was initially named Jingdezhen Fuxiang Pharmaceutical Co., Ltd. before adopting its current designation in August 2012.
- ISIN
- CNE1000024Z7
- Founded
- 2002
- Listed since
- Dec 22, 2015
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,247.37 | -0.64% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.00 | +1.02% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.91 | -1.08% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.14% |
Figures last refreshed Aug 18, 2026.